In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Inc.

www.abbvie.com

Latest From AbbVie Inc.

Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy

The latest drug development news and highlights from our FDA Performance Tracker.

US FDA Performance Tracker Drug Review

Pharma Q3 Results Preview: Biogen, Gilead, Celgene

Ozanimod re-filing is a big near-term catalyst for Celgene. Biogen investors will be looking for more information about the development and regulatory strategy for BAN2401 in Alzheimer's. And Gilead investors want reassurance that the company will return to growth soon. 

Sales & Earnings Business Strategies

Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing

Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its genomic capabilities. Aclaris licenses dermatology product Rhofade from Allergan. Other recent licensing and alliance deals... 

Deals Business Strategies

AbbVie Buys In On Morphic’s Oral Integrin Inhibitors, To Tune Of $100m

After years of industry unsuccessfully trying to find an oral version of the successful I.V. integrin inhibitors, Morphic has a prolific platform – and AbbVie is paying $100m up front for preclinical oral integrin inhibitors for fibrosis indications, potentially including NASH.

Deals Liver & Hepatic
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Big Pharma
  • Parent & Subsidiaries
  • AbbVie Inc.
  • Senior Management
  • Richard A Gonzalez, Chmn. & CEO
    William J Chase, EVP, CFO
    Michael E Servino, MD, EVP, R&D & CSO
    Carlos Alban, EVP, Commercial Ops.
  • Contact Info
  • AbbVie Inc.
    Phone: (847) 937-6100
    1 N. Waukegan Rd.
    North Chicago, IL 60064
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register